Collision tumor of the thyroid – a challenge during the COVID-19 pandemic

Mihaela Vlad, Ana Corlan, Melania Balas, Ioana Golu, Daniela Amzar, Emil Bistrian, Marioara Cornianu

Abstract


Some of the patients with anaplastic thyroid carcinomas have a coexistent differentiated thyroid cancer, sustaining the hypothesis that this cancer may develop from more differentiated tumors. We describe a case with a collision tumor of the thyroid, defined as a neoplastic lesion composed of two distinct cell populations, with distinct borders. The patient presented during the COVID-19 pandemic with dysphonia, dyspnea, multinodular goiter and a painless, rapidly enlarging, left cervical swelling. She had been first time diagnosed with left nodular goiter in 2007, with an indication for surgery, which she declined. After partial excision of the left latero-cervical adenopathy, the pathological analysis showed massive lymph node metastasis from anaplastic thyroid cancer. A total thyroidectomy was done; the postoperative pathological exam identified a papillary thyroid microcarcinoma in the right lobe and an anaplastic thyroid cancer in the left lobe. Postoperatively, levothyroxine treatment was started and the patient was referred to radiotherapy. This case highlights the importance of urgent management of some cases with compressive multinodular goiter, even during the COVID-19 pandemic.

Keywords


collision tumor; anaplastic thyroid cancer; papillary thyroid microcarcinoma; dedifferentiation

Full Text:

PDF

References


Ragazzi M, Ciarrocchi A, Sancisi V, Bisagni A, Piana S. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. 2014; 790834. https://doi.org/10.1155/2014/790834

Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006; 13(4):453-464. https://doi.org/10.1245/ASO.2006.05.042

Scosyrev E, Messing J, Noyes K, Veazie P, Messing E. Surveillance epidemiology and end results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol. 2012; 30(2):126-132. https://doi.org/10.1016/j.urolonc.2009.11.005

Yau T, Lo CY, Epstein RJ, Lam AKY, Wan KY, Lang BH. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol. 2008; 15(9):2500-2505. https://doi.org/10.1245/s10434-008-0005-0

McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001; 130(6):1028-1034. https://doi.org/10.1067/msy.2001.118266

Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103(7):1330-1305. https://doi.org/10.1002/cncr.20936

Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995; 17(1):41-47. https://doi.org/10.1002/hed.2880170109

Nel CJ, van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc. 1985; 60(1):51-58. https://doi.org/10.1016/s0025-6196(12)65285-9

Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985; 83(2):135-158. https://doi.org/10.1093/ajcp/83.2.135

Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine - refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009; 69(11):4885-4893. https://doi.org/10.1158/0008-5472.CAN-09-0727

Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017; 14(5):587-595. https://doi.org/10.1016/j.jacr.2017.01.046

Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006; 13(2):119-128. https://doi.org/10.1177/107327480601300206

Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996; 40(5):953-958. https://doi.org/10.1159/000334007

Takano K, Kikuchi K, Matsumiya H, Himi T. Collision tumor of the thyroid: follicular carcinoma plus papillary carcinoma plus adenomatous goiter. World J Med Surg Case Rep. 2013; 2:21-25.

Molnar C, Molnar S, Bedekovics J, et al. Thryoid carcinoma coexisting with Hashimoto’s thyroiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res. 2019; 25(3):1191-1197. https://doi.org/10.1007/s12253-019-00580-w

Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 1992; 18(2):83-88.

Saunders CA, Nayar R. Anaplastic spindle-cell squamous carcinoma arising in association with tall-cell papillary cancer of the thyroid: a potential pitfall. Diagn Cytopathol. 1999; 21:413-418. https://doi.org/10.1002/(sici)1097-0339(199912)21:6<413::aid-dc10>3.0.co;2-n

Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126:1052-1066. https://doi.org/10.1172/JCI85271

Rushton S, Burghel G, Wallace A, Nonaka D. Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma. Histopathology. 2016; 69:524-526. https://doi.org/10.1111/his.12964

Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600E – mutant anaplastic thyroid cancer. J Clin Oncol. 2018; 36:7-13. https://doi.org/10.1200/JCO.2017.73.6785

Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E - mutated anaplastic thyroid carcinoma. Thyroid. 2019; 29(8):1036-1043. https://doi.org/10.1089/thy.2019.0133

Bible KC, Kebebew E, Brierley J, et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021; 31(3):337-386. https://doi.org/10.1089/thy.2020.0944

Anand A, Singh KR, Kushwaha JK, Hussain N, Sonkar AA. Papillary thyroid cancer and Hashimoto’s thyroiditis: an association less understood. Indian J Surg Oncol. 2014; 5(3):199-204. https://doi.org/10.1007/s13193-014-0325-4

Lun Y, Wu X, Xia Q, et al. Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013; 148(3):396-402. https://doi.org/10.1177/0194599812472426




DOI: http://dx.doi.org/10.22551/2021.33.0804.10189

Copyright (c) 2021 Mihaela Vlad, Ana Corlan, Melania Balas, Ioana Golu, Daniela Amzar, Emil Bistrian, Marioara Cornianu

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

ISSN: 2360-6975